New biologic drug ASKG915 enters human trials for Hard-to-Treat cancers

NCT ID NCT05867420

Recruiting now Disease control Sponsor: AskGene Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new biologic drug called ASKG915, given alone or with standard chemotherapy, in about 594 people with advanced solid tumors that have stopped responding to other treatments. The main goals are to check safety and find the best dose. The trial is currently recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASKG915 (a biologic drug given by IV)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial focused on safety and dosing, so it is not yet known if ASKG915 will effectively shrink tumors. Side effects are possible, and the drug may not work for all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 201321, China
Peking University Cancer Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100089, China
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.